The Evolving Field of Treatment ModalitiesVideo Categories: 2018 AONN Midyear, Immunotherapy, and Video Library
Dr Morganna Freeman considers the future application of treatment modalities and how they might be combined for optimal results.
In this second clinical commentary entitled, Management of Patients with Basal Cell Carcinoma not Eligible for Surgery or Radiation, Joel Claveau, MD, CSPQ, FRCPC; Dirk Schadendorf, MD; Nicole Basset-Seguin, MD, PhD and Aleksandar Sekulic, MD, PhD discuss the need for new treatment options in the care of basal cell carcinoma [ Read More ]
Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.